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Patient profile Ondansetron
I v=Mnt ravenous. * Self-reported efficacy for vertigo control: 0=none; +=mild help; ++=moderate help; +++=major help.
Table: Effect of treatment with ondansetron on 7 patients with central vertigo
Age Disease Symptoms Signs Previous infective 
treatment {s)
Daily dose 
(mg)
Duration of 
treatment
Efficacy* Side-effects Response to 
rechallenge
39 MS Vertigo, nausea, 
vomiting
Nystagmus, ataxia Methylprednisolone,
dimenhydrinate,
lorazepam
8-12 12 weeks +++ None Yes
41 MS Vertigo, nausea, 
disequilibrium
Nystagmus, ataxia, 
spasticity
Dimenhydrinate 8 13 days ++ None Yes
35 Possible MS Vertigo, nausea, 
disequilibrium
Ataxia Meclizine-niacin,
dimenhydrinate
8 3 days + Headache Not tried
31 MS Vertigo, nausea Nystagmus, ataxia Lorazepam 8 8 weeks +++ None Yes
35 MS Vertigo, nausea Nystagmus Methylprednisolone 8 3 days +++ None Not tried
62 Pontine
haemorrhage
Headache, nausea, 
vertigo, vomiting, 
weakness
Gaze palsy, ataxia,
quadriparesis,
dysarthria
Lorazepam, 
metoclopramide (iv)
8 14 days ++ None Not tried
54 Wallenberg
syndrome
Vertigo, nausea, 
vomiting
Ataxia, dysarthria, 
Horner’s syndrome
Metoclopramide (iv) 8 8 days +++ None Not tried
This pilot experience warrants a further formal study of 
ondansetron compared with standard agents. The 5~HT3 
receptor axis might play a part in the pathogenesis of some 
syndromes of central vertigo.
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Interval cancers in hereditary non-polyposis 
colorectal cancer (Lynch syndrome)
Sir—H ereditary non-polyposis colorectal cancer (HNPCC) 
is an autosomal dominantly inherited disease caused by loss 
of function of a mismatch repair gene. It is characterised by 
the development of colorectal cancer at an early age, a 
predilection for tumours in the proximal colon, an excess of 
multiple colorectal cancers, and an association with various 
extracolonic cancers including endometrial cancer.1 Periodic 
examination of high-risk family members may prevent 
development of disease and death from cancer. Because of 
the high frequency of the H N PCC gene in the population 
(between 1 in 200 and 1 in 2000) and the fact that young 
people are involved, surveillance programmes in high-risk 
families should be an important goal of national health-care 
programmes. Identification of gene carriers within these 
families is of great importance because surveillance may be 
restricted to these relatives, and the relatives who do not 
carry the gene may refrain from examination, The 
recommended surveillance protocol for HNPCC 
(colonoscopy at 2-3 year intervals from age 20-25) is based 
on the hypothesis that the adenoma-carcinoma sequence, 
which is generally accepted in sporadic colorectal cancer, is 
also applicable in H N PCC. Observations from the US 
National Polyp Study indicate that it takes a mean of 10-12 
years for a polyp to develop and degenerate into a gross
cancer,2’3 which suggests that an interval of 2-3 years is 
adequate. In the Netherlands one of the largest series of 
HNPCC families (51 families including 394 first-degree 
relatives, mean follow-up 5 years) participates in a 
nationwide surveillance programme that is financially 
supported by the government, An unexpectedly high 
occurrence of advanced cancers was detected within 3*5 
years after a negative screening examination (table), Another 
unexpected finding was that most of the adenomas (about 
60%) detected in patients under surveillance were located in 
die distal part of the colon and the rectum, an observation 
that does not correspond with the anatomical distribution of 
carcinomas in HNPCC.
A possible explanation for the high frequency of interval 
cancers in our screening programme is that adenomas were 
missed during the previous screening examination. However, 
another explanation, which ties in with the discrepancy in 
location of adenomas and cancers in the colon, is that the 
HNPCC gene accelerates the processes of initiation and 
progression of cancer even in very small adenomas which are 
reported to be evenly distributed along the large intestine,4 
This explanation is also in agreement with a study5 that 
revealed that adenomas in HNPCC more often show a
«
villous growth pattern and a high degree of dysplasia than 
adenomas in a necropsy series, though there was no 
difference in size of the adenomas. A third explanation is 
that gene carriers develop “de novo” cancers.
On the basis of these findings we recommend a shortening 
of the interval between examinations to 1-2 years in proven 
gene carriers who have a risk of about 85% of developing 
colorectal cancer. A barium enema should be done when the 
colon is not completely visualised during endoscopy. 
Prophylactic subtotal colectomy may be considered in 
patients with (recurrent) polyps with a high degree of 
dysplasia or with a villous growth pattern. On the other hand 
prophylactic surgery in gene carriers without any colonic 
abnormalities should probably be avoided because of the
Patient*/®6* Age at Location Stage Previous interval
diagnosis of (Dukes) negative •
(F) tumour examination
1/M 46 R C Colonoscopy 2 yr, 7 mo
2 /F 46 R 8 Colonoscopy 2 yr
at/F 41 R C Barium enema 2 yr, 6 mo
4/M 40 R B Colonoscopy 3 yr, 6 mo
5 /F 53 R B Colonoscopy 3 yr
6/F 51 R C Colonoscopy 2 yr, 2 mo
*3 patients were symptomatic and 3 symptom free. 
jDled from colorectal cancer.
Relocated in ascending or transverse colon.
Table: Patients with colorectal cancer detected after negative 
screening examination
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morbidity that would be associated with this operation and 
because of the chance that individuals (10—20%) will never 
develop colorectal cancer. Reluctancy to undertake 
prophylactic surgery seems to be justified because H N PC C  
patients are at risk for development of cancer in various
organs.
*H FA Vasen, F M  Nagengast, P Meera Khan
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Adjuvant intraportal chemotherapy for 
colorectal cancer
SIR—The Swiss Group for Clinical Cancer Research 
(SAKK.) report perioperative intraportal mitomycin and 
fluorouracil for colorectal cancer (Feb 113 p 349). This 
study shows a modesty though statistically significant, 
survival advantage for patients randomised to chemotherapy 
when compared with those receiving no adjuvant treatment.
The Swiss group investigators state in their concluding 
paragraph that they now accept perioperative adjuvant 
chemotherapy as the standard treatment for further clinical 
trials in colorectal cancer. Although most would agree that 
treatment for node-positive colorectal cancers should now 
include some form of adjuvant therapy, we cannot find any 
justification for treating Dukes5 B (T3-4,N0,M0) cases in a 
similar manner. This group of patients* constituting over a 
third of all colorectal cancer cases, has a 5-year survival 
in excess of 70% without adjuvant treatment* and there are 
few published data1 or data in the SAKK study to suggest 
that this survival rate is improved by conventional 
chemotherapeutic regimens.
The data provided by SAKK do not include an overall or 
disease-free survival curve for node-negative patients 
stratified by treatment. However, the percentage of tumour 
recurrences was almost identical in treated and untreated 
groups (27% vs 29%), and the small difference in cancer- 
related 5-year survival (5%) with extensively overlapping 
SEs in the two groups suggests that any survival advantage 
attributable to chemotherapy is marginal in these node­
negative cases. In addition, the hypothesis that portal 
chemotherapy might reduce the frequency of liver 
metastases in node-negative patients has clearly not been
validated, since there were 60% fewer cases of isolated liver
i
metastasis in the control group. Indeed, locally recurrent 
disease accounted for over 50% of all recurrences in the 
untreated group, suggesting that improved surgical 
techniques rather than adjuvant therapy might be of greater 
benefit to these node-negative patients.
The inclination to administer conventional adjuvant 
therapies to virtually all patients with colorectal cancer may 
be compelling, but we believe that the temptation should be 
resisted in non-metastatic cases in the absence of any 
supporting data. An alternative policy of enrolling Dukes’ B
patients into controlled trials of new agents,2 while giving 
conventional regimens to selected high-risk cases/ might 
greatly improve survival in the node-negative group while 
sparing most such cases unnecessary and potentially toxic
treatments.
*Hugh E Muicahy, Michael J G Farthing
Digestive Diseases Research Centro, Medical College of St Bartholomew's Hospital, 
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Authors' reply
Sir—M uicahy and Farthing’s comment allows us the 
opportunity to emphasise the fact that we regard our 
perioperative regimen as standard treatment only for further 
clinical research in colon cancer. We are certain that our 
results do not justify the routine use of this regimen for 
patients outside clinical trials.
Perioperative adjuvant treatments could be tested in u 
patient population before the full histopathological staging 
took place. The overall results of the study show an 
estimated 21 % reduction of the chance of relapse and 20% 
reduction of the likelihood of death for patients given 
perioperative treatment compared with controls. The 
magnitude of the effect and the reasonably small degree of 
statistical uncertainty (range of 95% CIs and p values) 
allowed us to formulate the conclusions. Retrospeciive 
subgroup analysis, as in the one that led to defining 
treatment results by nodal status, are mainly useful for the 
generation of new research, rather than to justify a policy for 
routine patient care.
The estimated 14% reduction in the risk of relapse in the 
subpopulation without lymph-node inetastases, although 
statistically uncertain, indicates that some patients with such 
disease presentation might benefit from the treatment. On 
the other hand, the 5-year estimated baseline disease-free 
survival was 63% (SD 4%), which indicates an important 
opportunity for improvement. This treatment is, therefore* 
die strategy chosen by SAKK to further investigate whether 
the addition of a prolonged treatment might lead to 
improved outcome, even for patients without lymph-node 
metastases.
Aron Goldhirsch, *Urban Th Laffer, Urs Metzger,
Peter Aeberhard, Rued/ Maibach, Monica Castigiione, 
for the Swiss Group for Clinical Cancer Research
Surgical Clinic, Regionalspltnl Biol, CH 2502 Biol Olenno, Switzerland
Leprosy
Sir—T he gTand round on leprosy (March IB, p 697) was an 
eye opener for physicians in the developed world. In the 
present immigrant era, no nation is shielded from this 
crippling disease of the developing world, where the 
associated social stigmata parallels that of AIDS in western 
countries. The training that physicians receive for leprosy in 
developed nations is so grossly inadequate that there might 
be a danger of failing to recognise and manage the disease 
appropriately. However, with the low caseloads and the 
abundant financial resources in developed countries leprosy 
is unlikely to affect western populations with the same 
tenacity as is seen in the third world.
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